NVIV News and Press, InVivo Therapeutics Holdings Corp. From 03/09/23

Study did not achieve primary endpoint of defined improvement on standard impairment scale InVivo to evaluate full data set and strategic options for the company InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology compa...

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has closed its previously announced registered direct offering for the sale and issuance...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: stockphoto-graf / Shutterstock.com Visa (NYSE: V ) stock is on the move following news that the company and FTX are teaming up to bring debit cards tied to crypto accounts to a wealth of countries. T...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: ra2 studio/Shutterstock InVivo Therapeutics (NASDAQ: NVIV ) stock is on the move Friday after the company reached a deal for a direct offering of its shares. The registered direct offering has InVivo...

InVivo Therapeutics ( NASDAQ: NVIV ) entered agreement with a single healthcare-focused institutional investor for the sale and issuance of 523,810 shares. Concurrently entered into a definitive agreement with the investor in the registered direct offering for t...

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional i...

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcom...

Gainers: CinCor Pharma CINC +66% . Karuna Therapeutics KRTX +61% . 23andMe ( ME ) +22% . Cerevel Therapeutics ( CERE ) +20% . Quoin Pharmaceuticals ( QNRX ) +16% . Losers: Reata Pharmaceuticals RETA -31% . uniQure QUR...

NuZee ( NUZE ) -24% on pricing $3.4M stock offering . Reata Pharmaceuticals ( RETA ) -20% on Q2 earnings release . Palantir Technologies ( PLTR ) -14% on Q2 earnings release . Digital World Acquisition ( DWACW ) -10% . Cognit...

Hyzon Motors ( HYZN ) -36% after disclosing operational inefficiencies, financial issues . Helius Medical Technologies ( HSDT ) -30% . Quoin Pharmaceuticals ( QNRX ) -23% . Chembio Diagnostics ( CEMI ) -18% on Q2 earnings release . ...